Camolyn Eye Drop and Fisiolin Nasal Drop Recall: Drops May Be Non-Sterile
A recall of all Camolyn Eye Drops and Fisiolin Nasal Drops has been issued after it was discovered that they may not be sterile, which could cause infections or blindness.
The nasal and eye drop recall was announced on Wednesday by FDA. According to a press release from the manufacturer, US Oftalmi Corporation, the recall was initiated after it was determined that conditions in the manufacturing facility could not guarantee the sterility of the drops. However, there have been no injuries or reports of problems from consumers.
The Camolyn Eye Drops recall and Fisiolin Nasal Drops recall affects all over-the-counter drops under those labels, including Camolyn Homeopathic; Camolyn Plus, Naphazoline + Chamomile; Camolyn Refresh; Camolyn-A, Naphazoline + Pheniramine; and Fisiolin Nasal Drops Sodium Chloride Pediatric Uses. All of the recalled eye drops and nasal drops were distributed nationwide to food and drug distributors and were packaged in 15 mL plastic bottles.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
If a consumer uses non-sterile drops, they could develop an infection. Some eye infections could potentially lead to blindness. However, US Oftalmi has said that it believes the likelihood of users experience a severe adverse reaction is remote.
The company has ceased production of the nasal and eye drops until the manufacturing problem can be solved. It is recommended that any consumers with the recalled eye and nasal drops discard them immediately.
Anyone who experiences an adverse reaction from this product should report the incident to the FDA’s MedWatch Program at www.fda.gov/medwatch.
"*" indicates required fields
More Top Stories
Uber faces a lawsuit from four passengers who say they were sexually assaulted by drivers, due to the company's lack of security measures and focus on passenger safety.
A Bard PowerPort lawsuit claims the defective design of the port catheter led to a woman developing a severe infection and needing to have the implant surgically removed.
The new federal judge overseeing all talcum powder lawsuits has called for a Science Day to educate the court ahead of planned Daubert hearings which could decide if bellwether test trials can move forward.